{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.801","value":"8.63"},{"groupId":"OG001","spread":"5.804","value":"9.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Response will be determined by a blinded centralized review of volumetric MRI. Time to response is defined as the time in months from the start of treatment to the date of first response that was subsequently confirmed.","dispersionType":"Standard Deviation","groups":[{"description":"Patients aged 2 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901)"},{"description":"Patients aged 18 and above at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Adult Cohort Mirdametinib (PD-0325901)"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set patients who achieved confirmed objective response.","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Time to Response Defined as the Time Between First Dose and the First Date of Objective Response That is Subsequently Confirmed.","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}